Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...
Collaboration to expand research and molecular breeding tools for enhancing plant, crop, and livestock production outcomes SANTA CLARA, Calif.--(BUSINESS WIRE)-- Affymetrix, Inc. (NASDAQ:AFFX), ...
Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since ...
HOUSTON & SANTA CLARA, Calif.--(BUSINESS WIRE)--Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (NASDAQ:AFFX) today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories ...
Ingenuity Systems and Affymetrix will be co-promoting Ingenuity® iReport™ with Affymetrix’ expression microarray products to help eliminate a bottleneck for researchers working with human, mouse, and ...
Affymetrix, Inc. (NASDAQ:AFFX) today announced that it has signed a distribution agreement with Fisher Scientific, Inc., part of Thermo Fisher Scientific, to distribute the GeneAtlas™ System and its ...
Mindy Lee-Olsen, 408-731-5523 (Media)Vice President, Marketing ServicesorDoug Farrell, 408-731-5285 (Investors)Vice President, Investor Relations (NASDAQ:AFFX) announced today the availability of ...
SANTA CLARA, Calif. -- Affymetrix today announced that it has signed an agreement with Avesthagen Limited, a leading biotechnology company based in Bangalore, India. Under the terms of the agreement, ...
Microarray technologies are generating new data at a breathtaking speed. Because of the sheer size of these data and the technical complexity involved in microarray chip designs, it is a challenge to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results